4.5 Article

Dedifferentiated Chordoma Clinicopathologic and Molecular Characteristics With Integrative Analysis

期刊

AMERICAN JOURNAL OF SURGICAL PATHOLOGY
卷 44, 期 9, 页码 1213-1223

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PAS.0000000000001501

关键词

chordoma; dedifferentiated chordoma; dedifferentiation; brachyury; p53; INI1

资金

  1. Agios
  2. ACD Biotechne
  3. Epizyme
  4. PharmaMar
  5. Eisai
  6. Merck KGaA/EMD Serono Research and Development Institute
  7. Amgen
  8. Bayer
  9. Bavarian-Nordic
  10. Boston Biomedical
  11. CBA
  12. Macrogenics
  13. Otsuka
  14. Plexxicon
  15. SpringWorks Therapeutics

向作者/读者索取更多资源

Dedifferentiated chordoma is a rare chordoma subtype characterized by a high-grade sarcoma juxtaposed to conventional chordoma. We identified a series of dedifferentiated chordomas, reviewed clinicopathologic features, performed next-generation sequencing in select cases, and analyzed all related English-language publications. Our series included 7 men and 3 women (age 15 to 80 y [median: 54 y]; 1000 chordomas surveyed). The tumor (2.8 to 24.5 cm [median: 5.8 cm] in size) presented de novo or as recurrence (including postradiotherapy) in sacrum (n=5), skull base (n=2), lumbar spine (n=1), thoracic/mediastinum (n=1), and lung (n=1; as metastasis). Histologically, the dedifferentiated component (3% to 95% [median: 60%]) was pleomorphic-to-fibrosarcomatous, juxtaposed to conventional (n=8) or chondroid (n=2) component. By immunohistochemistry, the conventional/chondroid component consistently expressed cytokeratin and brachyury, whereas the dedifferentiated component showed loss of both. We identified a sacral conventional chordoma with INI1 loss, with one of the lung metastases showing biphasic histology with loss of cytokeratin and brachyury in the dedifferentiated component. Sequencing identified tumor suppressor mutations in 4 tumors, includingTP53mutations in the dedifferentiated component in 3 tumors. Of 7 patients with follow-up, 6 developed metastases; 4 died at 15 to 99 months (median: 24 mo) after dedifferentiated chordoma diagnosis. Collectively, of 87 dedifferentiated chordoma patients described in 1913-2020 (including 10 herein), the median overall survival was 20 months. In summary, dedifferentiated chordoma involves diverse sites and presents de novo, postradiotherapy, or as recurrence/metastasis months-to-years after initial diagnosis. The dedifferentiated component shows loss of brachyury and cytokeratin staining and harbors recurrentTP53mutations, implicating tumor suppressor dysregulation in chordoma dedifferentiation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据